Bridging a Lack of Diversity in Clinical Trial Populations
Event Information
About this Event
Medical Affairs: bridging a lack of diversity in clinical trial populations and real world medicine use
In this online lecture, Professor Graham McClelland presents the scientific evidence acquired by King’s MSc students, on the lack of diversity in clinical trial populations .
Part of King's College London's Transforming the Future of Healthcare keynote lectures.
If you are unable to make this time we are running this talk in the morning. Please book here.
Medical Affairs is a fast-growing function with the pharmaceuticals sector, serving as the bridge between the industry and its stakeholders via the medical community.
In this lecture, Professor Graham McClelland presents the scientific evidence acquired by King’s MSc students, on the lack of diversity in clinical trial populations. These trials are carried out as part of licencing a medicine, after which Medical Affairs professionals translate the data for the dosing of patients that live in the real world.
This lecture will be of particular interest to students and graduates of biomedical sciences, pharmacy, medicine and those with an interest in understanding the process of drug development and the role of medical affairs.
This is your chance to learn more about our courses, research and the department, as well as to ask any questions you might have. Please note we are running this event twice to suit different time zones and the webinar link will be sent to you prior to the event once registered.
We look forward to meeting you online!
About King’s
Ranked 14th in the world for Pharmacy& Pharmacology (QS World Rankings), King's Institute of Pharmaceutical Sciences is the leading European academic provider of education in pharmaceutical medicine including expertise in the field of medical affairs.
About Professor Graham McClelland
Prof Graham McClelland is a Visiting Professor in the Centre of Pharmaceutical Medicine Research of the Faculty of Life Sciences & Medicine at King’s College London. He spent over 30 years working in R&D for the pharmaceutical industry with Beecham (now part of GlaxoSmithKline) and Roche, holding senior international leadership positions in clinical research. He is a qualified biologist, psychologist and pharmacologist, and obtained his PhD in clinical psychopharmacology from Hatfield Polytechnic by part-time study.
Graham has published over 60 book chapters and research articles, holds 3 patents, and has spoken and chaired conferences across the globe. He has served as a member of several advisory bodies including for the ABPI, the Department of Health, the charity Ataxia UK, and as an adviser to businesses including the independent sustainability consultancy company, Article 13. In 2018 he joined King’s as a Visiting Professor, where teaches on the pharmaceutical medicine MSc programmes. He currently has broad research interests in the development of new medicines and in corporate social responsibility in the pharmaceutical industry.
From Molecules to Medicines: Using Science to Transform Healthcare
The Institute of Pharmaceutical Science at King’s College London works towards the discovery of novel medicines and new formulations that can be evaluated in patients in the clinic, as well as providing a better understanding of how to optimise the use of existing medicines.
The Institute is part of the School of Cancer and Pharmaceutical Sciences with a mission to improve patient response through fundamental science discovery. Home to 300 members of staff (including 80 Principal Investigators) and 200 PhD students, the School’s academic excellence is widely recognised: ranked 13th in the world for Pharmacy and Pharmacology (2020 QS subject rankings) and first in the UK for Clinical Medicine in terms of the proportion of King’s overall submission that was ranked 4* or 3* (REF2014). Through the School’s partnership with King’s Health Partners, our scientists are joining up with world-class clinical services for the benefit of cancer patients in south east London and beyond. Working across our acute and community sectors, we are also maximising beneficial outcomes for our patients from medicines, through medicines optimisation.
Postgraduate courses include:
